| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/24/2010 | EP2155227A1 New treatment for chemical substance addiction |
| 02/24/2010 | EP2155204A1 Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| 02/24/2010 | EP2155191A1 Transglutaminase inhibitor comprising egcg and a method for producing thereof |
| 02/24/2010 | EP2155184A2 Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies |
| 02/24/2010 | EP2155183A1 Amino acid derivatives as calcium channel blockers |
| 02/24/2010 | EP2155181A1 5-htp combination therapy |
| 02/24/2010 | EP2155179A1 Axomadol for treating pain from arthritis |
| 02/24/2010 | EP2154962A1 Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
| 02/24/2010 | EP2059520B1 1,4,5,6,7,8-hexahydro-i,2,5-triaza-azulene derivatives as orexin receptor antagonists |
| 02/24/2010 | EP2029596B1 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzothiazepines, the preparation and use thereof, and compositions containing the same |
| 02/24/2010 | EP1981880B1 Use of 4-imidazole derivatives for cns disorders |
| 02/24/2010 | EP1931335B1 Hexahydro cyclooctyl pyrazole cannabinoid modulators |
| 02/24/2010 | EP1928484B1 Methods for treatment of headaches by administration of oxytocin |
| 02/24/2010 | EP1808432B1 Amorphous form of cinnamide compound |
| 02/24/2010 | EP1789057B1 Neuroprotective effect of solubilized udca in focal ischemic model |
| 02/24/2010 | EP1748995B1 Arylsulfonyl benzodioxanes useful for modulation the 5-ht6 receptor, the 5-ht2areceptor or both |
| 02/24/2010 | EP1615615B1 Tamper-resistant products for opioid delivery |
| 02/24/2010 | EP1572066B1 Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within mmp-2 |
| 02/24/2010 | EP1542678B1 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB sb 1 /sb RECEPTOR LIGANDS |
| 02/24/2010 | EP1325130B1 Nogo receptor homologs |
| 02/24/2010 | EP1033979B2 Combination of cyp2a6 enzyme inhibitors and nicotine and their therapeutic use |
| 02/24/2010 | EP0861261B9 Nucleotide and protein sequences of vertebrate delta genes and methods based thereon |
| 02/24/2010 | CN101654479A Mammalian receptor proteins, agents, and methods relating thereto |
| 02/24/2010 | CN101654423A Process for the preparation of and crystalline forms of optical enantiomers of modafinil |
| 02/24/2010 | CN101653604A Anti-ngf antibodies for the treatment of various disorders |
| 02/24/2010 | CN101653411A Controlled release hydrocodone formulations |
| 02/24/2010 | CN100591680C Dihydrotetrabenazines and pharmaceutical compositions containing same |
| 02/24/2010 | CN100591360C New application of chromaffin cell of adrenal medulla or opium peptide energy cell |
| 02/24/2010 | CN100591329C Montelukast granule formulation |
| 02/24/2010 | CN100591320C Stable surfactant compositions for suspending components |
| 02/23/2010 | USRE41151 Comprising a modified NSAID, wherein the NSAID is covalently attached either directly or through a linker molecule to a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety; nonsteroidal anti-inflammatory drugs; side-effect reduction |
| 02/23/2010 | USRE41150 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 02/23/2010 | USRE41148 Comprising an immediate-release component and an enteric delayed-release component; amphetamine aspartate and sulfate salts, dextroamphetamine saccharate or sulfate salts; FDA listed patent for Adderall XR 10 |
| 02/23/2010 | US7667053 Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders |
| 02/23/2010 | US7667041 Cinnamide compound |
| 02/23/2010 | US7667040 Azacyclic ethynyl derivatives |
| 02/23/2010 | US7667036 Pyrazolo[1,5-a]pyrimidine derivatives |
| 02/23/2010 | US7667008 Heparin binding protein for use in controlling angiogenesis and as wound healing agent |
| 02/23/2010 | US7666995 Interferons, uses and compositions related thereto |
| 02/23/2010 | US7666909 Enhancement of alcohol metabolism |
| 02/23/2010 | US7666906 β-Benzyloxyaspartate derivatives with amino group on benzene ring |
| 02/23/2010 | US7666892 N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}-4-(4-fluorophenoxy)benzenesulfonamide and N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}[1,1'-biphenyl]-4-sulfonamide; chemical intermediates for enzyme inhibitors; especially as inhibitors of MMP12 |
| 02/23/2010 | US7666885 Enzyme inhibitors |
| 02/23/2010 | US7666876 Buprenorphine formulations for intranasal delivery |
| 02/23/2010 | US7666867 Heteroindanes: a new class of potent cannabimimetic ligands |
| 02/23/2010 | US7666848 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics |
| 02/23/2010 | US7666675 Hair follicle stem cells for use in the treatment of nervous system disorders and cell therapy |
| 02/23/2010 | US7666647 Unphosphorylated glycogen synthase kinase-3-g-beta (GSK) from baculovirus overexpression system; competitive binding; diabetes, Alzheimer's disease |
| 02/23/2010 | US7666422 Methods for the treatment of cancer using anti-CD40 antibodies |
| 02/23/2010 | US7666401 Compositions comprising a ligand of Chemerin R |
| 02/23/2010 | US7666398 Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| 02/23/2010 | CA2463446C Use of (11.beta., 17.beta.)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder |
| 02/23/2010 | CA2462289C Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| 02/23/2010 | CA2446890C Deuterated 3-piperidinopropiophenones and pharmaceutical drugs containing these compounds |
| 02/23/2010 | CA2378880C Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 02/23/2010 | CA2335461C Calcium channel blockers |
| 02/23/2010 | CA2257852C Transgenic non-human mammals with progressive neurologic disease |
| 02/20/2010 | CA2682471A1 Method and dosage regimens for eliminating a chemical substance in blood |
| 02/18/2010 | WO2010019560A1 Deuterated derivatives of donepezil |
| 02/18/2010 | WO2010019275A2 Compositions and methods for treatment during non-acute periods following cns neurological injury |
| 02/18/2010 | WO2010019101A1 A crystalline form of 4- (5-{ (ir) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } - 4 -methyl- 4h- 1, 2,4- triazol-3-yl) pyridine |
| 02/18/2010 | WO2010019100A1 A new crystalline form of 4- (5- { (ir) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } -4-methyl-4h-l, 2, 4- triazol-3-yl) pyridine |
| 02/18/2010 | WO2010018856A1 Prophylactic/ameliorating or therapeutic agent for cannabinoid receptor-related disease |
| 02/18/2010 | WO2010018837A2 Protein cross-linking inhibitor |
| 02/18/2010 | WO2010018836A2 Polyglutamine aggregation inhibitor |
| 02/18/2010 | WO2010018800A1 Acetyl pyrrolidinyl indole derivative |
| 02/18/2010 | WO2010018652A1 Agent for promoting neuronal differentiation and method therefor |
| 02/18/2010 | WO2010018408A2 Pharmaceutical compositions |
| 02/18/2010 | WO2010018329A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 02/18/2010 | WO2010018328A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 02/18/2010 | WO2010018327A1 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-ib]-pyridazine derivatives, preparation thereof, and therapeutic application thereof |
| 02/18/2010 | WO2010018280A1 Use of p2x7 receptor antagonists to promote axonal growth and ramification |
| 02/18/2010 | WO2010018231A2 Salt of, and processes for the preparation of, 1-isopropyl-4-{[4-(tetrahydro-2h-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1h-1,4-diazepine |
| 02/18/2010 | WO2010018214A1 Pyrrolidinone derivatives useful for the treatement of psychotic and neurological disorders |
| 02/18/2010 | WO2010018182A1 Peptidic and peptidomimetic compounds for regulating autophagy |
| 02/18/2010 | WO2010018095A1 Salicylamide derivatives as nicotinic alpha 7 modulators |
| 02/18/2010 | WO2010017996A1 Use of low-dose local anaesthetic or derivatives thereof for therapy of chronic pain, especially migraine |
| 02/18/2010 | WO2010017912A2 Use of human hyaluronidases for axonal regrowth |
| 02/18/2010 | WO2010017626A1 Compositions comprising terpene compounds for treating negative sensory phenomena |
| 02/18/2010 | WO2010017598A1 Anti-il-12/il-23 antibodies |
| 02/18/2010 | WO2009155017A3 Novel substituted azabenzoxazoles |
| 02/18/2010 | WO2009092073A3 Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects |
| 02/18/2010 | WO2009012569A8 TREATING OR AMELIORATING A NEUROINFLAMMATORY OR DEMYELINATING DISORDER WITH PROLACTIN AND INTERFERON-β |
| 02/18/2010 | WO2008132712A3 Combination pharmaceutical compositions |
| 02/18/2010 | US20100041764 Therapeutic agent for diabetic neuropathy |
| 02/18/2010 | US20100041763 Salicylamide derivatives as nicotinic alpha 7 modulators |
| 02/18/2010 | US20100041759 Multi-phase release potassium guaiacolsulfonate compositions |
| 02/18/2010 | US20100041721 Selective androgen receptor modulators |
| 02/18/2010 | US20100041715 Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof |
| 02/18/2010 | US20100041709 Substituted n-(4-cyano-1h-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof |
| 02/18/2010 | US20100041707 Inhibitors of ion channels |
| 02/18/2010 | US20100041702 Benzimidazole cannabinoid agonists |
| 02/18/2010 | US20100041698 Heterocyclic compounds and their use as binding partners for 5-ht5 receptors |
| 02/18/2010 | US20100041680 Piperidine derivatives |
| 02/18/2010 | US20100041667 Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| 02/18/2010 | US20100041665 N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| 02/18/2010 | US20100041660 Novel 2-pyridinecarboxamide derivatives |
| 02/18/2010 | US20100041652 Tyrosine kinase inhibitors |
| 02/18/2010 | US20100041651 Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 02/18/2010 | US20100041647 3-Substituted-[1,2,3]-Benzotriazinone compounds for enhancing glutamatergic synaptic responses |